Eli Lilly and Company
|
|
- Morris Phillips
- 5 years ago
- Views:
Transcription
1 Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012
2 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by such factors as the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations. For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements. 2
3 Psoriasis Background Autoimmune disorder affecting the skin Roughly 7.5 million people in the U.S. have psoriasis; the most prevalent chronic autoimmune disorder 1 Estimated that roughly 17% of these patients have moderate-to-severe e o e e plaque psoriasis 1, requiring systemic therapy Underlying pathology of the disorder is not fully known but it is characterized by skin inflammation and infiltration by immune cells Inflammation thought to be linked to T-cell mediated immune response Interleukin-17A (IL-17) 17), a proinflammatory cytokine, is found in elevated levels in lesional psoriatic skin 1 National Psoriasis Foundation, About Psoriasis, Accessed Feb. 10,
4 Ixekizumab Profile Humanized digg4 monoclonal l antibody Binds to and neutralizes IL-17A (IL-17) High affinity and specificity for IL-17A Administered via subcutaneous injection 4
5 Study Design Study Population Moderate-to-severe chronic plaque psoriasis for at least 6 months Total of 142 patients; study sites in the U.S. and Denmark Randomized, d double-blind, bli d placebo-controlled, ll parallel l group study Doses (all subcutaneous): Placebo (n=27) ixekizumab 10 mg (n=28) ixekizumab 25 mg (n=30) ixekizumab 75 mg (n=29) ixekizumab 150 mg (n=28) Injection regimen: weeks 0, 2, 4,8, 12, 16 5
6 Endpoints and Measures Primary endpoint: Proportion of patients with at least 75% reduction in Psoriasis-Area-and- Severity-Index (PASI) scores (PASI 75) at 12 weeks Secondary measures included d (among others): PASI 90 (at least 90% improvement in PASI score) PASI 100 (100% improvement in PASI score) spga (static Physician Global Assessment) of 0 or 1 (clear or minimal disease) spga of 0 (clear of disease) Nail Psoriasis Severity Index (NAPSI) Psoriasis Scalp Severity Index (PSSI) 6
7 Baseline Characteristics Ixekizumab Characteristic a Placebo (N = 27) 10 mg (N = 28) 25 mg (N = 30) 75 mg (N = 29) 150 mg (N = 28) p-value b Age, years 45 ± ± ± ± ± Gender, male, n (%) 14 (52) 16 (57) 18 (60) 19 (66) 14 (50) 0.77 Weight, kg 92 ± ± ± ± ± Duration of psoriasis a, years 15 ± ± ± ± ± Previous systemic therapy, n (%) 13 (48) 12 (43) 9 (30) 6 (21) 10 (36) 0.22 BSA 19 ± ± ± ± ± PASI 16.5 ± ± ± ± ± spga 3.3 ± ± ± ± ± PSSI, (n) NAPSI, (n) 19.6 ± ± ± ± ± 12.0 (21) (21) (24) (18) (22) 35.0 ± 28.1 (17) 41.9 ± 44.8 (13) 34.9 ± 37.7 (10) 45.0 ± 46.9 (10) 46.5 ± 51.7 (10) DLQI 11.4 ± ± ± ± ± a Data presented in mean ± SD, unless otherwise mentioned, b p values are for comparisons across all treatment arms 7
8 PASI 75 At least 75% Improvement in PASI Scores from Baseline 100 % of Subjects Placebo LY 10 mg SC LY 25 mg SC LY 75 mg SC LY150 mg SC Treatment Arm %of patients at 12 weeks LY 150 mg 82 LY 75 mg 83 LY 25 mg 77 LY 10 mg 29 Placebo Weeks LY: ixekizumab SC: subcutaneous injections : treatment days p<0.05 versus placebo 8
9 PASI 90 At least 90% Improvement in PASI Scores from Baseline 100 Placebo Subject60 % of ts LY 10 mg SC LY 25 mg SC LY 75 mg SC LY150 mg SC Treatment Arm %of patients at 12 weeks LY 150 mg 71 LY 75 mg 59 LY 25 mg 50 LY 10 mg 18 Placebo Weeks LY: ixekizumab SC: subcutaneous injections : treatment days p<0.05 versus placebo 9
10 PASI % Improvement in PASI Scores from Baseline 100 Subjects60 % of Placebo LY 10 mg SC LY 25 mg SC LY 75 mg SC LY 150 mg SC Treatment Arm %of patients at 12 weeks LY 150 mg 39 LY 75 mg 38 LY 25 mg 17 LY 10 mg 0 Placebo LY: ixekizumab SC: subcutaneous injections : treatment days Weeks p<0.05 versus placebo 10
11 spga 0 Clear of Disease 100 Subject60 of s % Placebo LY 10 mg SC LY 25 mg SC LY 75 mg SC LY 150 mg SC Treatment Arm %of patients at 12 weeks LY 150 mg 46 LY 75 mg 38 LY 25 mg 20 LY 10 mg 7 Placebo Weeks LY: ixekizumab SC: subcutaneous injections : treatment days p<0.05 versus placebo 11
12 NAPSI Scores Nail Psoriasis Severity 100 Mean % Change Fr rom Baselin ne Placebo LY 10 mg SC LY 25 mg SC LY 75 mg SC LY 150 mg SC Weeks Treatment Arm Mean % change from baseline at 12 weeks LY 150 mg -49 LY 75 mg -57 LY 25 mg -24 LY 10 mg 14 Placebo 7 LY: ixekizumab SC: subcutaneous injections : treatment days p<0.05 versus placebo 12
13 PSSI Scores Scalp Psoriasis Severity ine Mean % Change From Basel Placebo LY10 mg SC LY 25 mg SC LY 75 mg SC LY 150 mg SC Treatment Arm Mean % change from baseline at 12 weeks LY 150 mg -85 LY 75 mg -95 LY 25 mg -87 LY 10 mg -43 Placebo -30 Weeks LY: ixekizumab SC: subcutaneous injections : treatment days p<0.05 versus placebo 13
14 Adverse Events Ixekizumab Placebo (N = 27) 10 mg (N = 28) 25 mg (N = 30) 75 mg (N = 29) 150 mg (N = 28) Total number of adverse events, n Serious adverse events At least 1 adverse event, n (%) 17 (63) 21 (75) 21 (70) 17 (59) 13 (46) Infections and infestations 7 (26) 12 (43) 9 (30) 9 (31) 8 (29) Nasopharyngitis c 5 (19) 3 (11) 3 (10) 3 (10) 4 (14) Upper respiratory infection 1 (4) 1 (4) 3 (10) 1 (3) 1 (4) Injection site reaction (10) 1(3) 2(7) Headache 1 (4) 4 (14) 4 (13) 1 (3) 1 (4) Allergy/hypersensitivity 2 (7) 1 (4) 1 (3) 2 (7) 1 (4) 14
15 Additional Safety Information No serious adverse events observed No significant change in mean neutrophil counts and no Grade 3 or 4 neutropenia observed Two basal cell skin carcinomas reported in one patient with a history of basal cell carcinoma; no other cancers observed Larger, longer-term studies are required to more fully characterize the safety profile of ixekizumab 15
16 Current Plans One Phase 3 trial ongoing in psoriasis: Initiated in December 2011 Randomized, double-blind, placebo-controlled Patients with chronic moderate-to-severe plaque psoriasis ~1,300 patients in the U.S., Canada, Europe, Japan and Australia Ixekizumab dosing mimics exposures at 75 mg and 150 mg doses in Phase 2 study Primary endpoints include spga 0or1andPASI75 Two additional Phase 3 trials in psoriasis to begin this year Evaluating options to study ixekizumab as a potential treatment for other autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis 16
Details of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet
June 10, 2015 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Refer to: Immediately Tim Coulom; tim.coulom@lilly.com; 317-771-2241
More informationThe 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909
The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 2-24, 215 Poster ID: 99 Clinical Efficacy and Safety of Brodalumab (KHK4827), Anti-Interleukin-17-Receptor A Fully
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationOTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Patients with moderate to severe plaque psoriasis
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationPRODUCT MONOGRAPH. (Secukinumab) Solution for injection Powder for solution for injection* 150 mg/1.0 ml. Biological Response Modifier
PRODUCT MONOGRAPH Pr COSENTYX (Secukinumab) Solution for injection Powder for solution for injection* 150 mg/1.0 ml Biological Response Modifier COSENTYX (secukinumab) should be prescribed only by health
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationJefferies Healthcare Conference June 8, 2017
Jefferies Healthcare Conference June 8, 2017 1 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME COSENTYX 150 mg Powder for Injection COSENTYX 150 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: Secukinumab Chemical name: Recombinant human
More informationEli Lilly and Company Investment Community Meeting
Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current
More informationChemical name: Recombinant human monoclonal anti-human Interleukin-17A (IL-17A, IL-17) antibody of the IgG1/kappa isotype
AUSTRALIAN PI COSENTYX (secukinumab [rch]) 150 mg/1 ml SOLUTION FOR INJECTION IN PREFILLED SYRINGE 150 mg/1 ml SOLUTION FOR INJECTION IN PREFILLED PEN 150 mg POWDER FOR INJECTION IN VIAL 1 NAME OF THE
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationResults Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that
More informationKim A. Papp, MD PhD Probity Medical Research, Waterloo, ON, Canada
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pooled Efficacy Results from the Subgroup of Canadian Patients in Two Phase III Randomized Controlled
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TALTZ ixekizumab Solution for Injection 80 mg / 1.0 ml Immunomodulator Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationConventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2.
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationM (SAPPHIRE-II)
PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationAnti Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Anti Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis Craig Leonardi, M.D., Robert Matheson, M.D., Claus
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationESPONDILOARTROPATÍAS. Dr. Julio Ramírez García
ESPONDILOARTROPATÍAS Dr. Julio Ramírez García Bloque 1: Caracterización de los pacientes con SpA axial ABSTRACT NUMBER: 1509 Similarities and Differences between Non-Radiographic and Radiographic Axial
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEdasalonexent (CAT-1004) Program
Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy Joanne M. Donovan, MD, PhD Chief Medical Officer, Catabasis Pharmaceuticals
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationGuselkumab (plaque psoriasis)
IQWiG Reports Commission No. A18-24 Guselkumab (plaque psoriasis) Addendum to Commission A17-60 1 Addendum Commission: A18-24 Version: 1.0 Status: 27 April 2018 1 Translation of addendum A18-24 Guselkumab
More informationInitial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment
Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationSYNOPSIS. Issue Date: 17 Jan 2013
STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &
More informationTremfya (guselkumab) NEW PRODUCT SLIDESHOW
Tremfya (guselkumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Tremfya Generic name: Guselkumab Pharmacological class: Interleukin-23 antagonist Strength and Formulation: 100mg/mL; soln for SC inj;
More informationADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA
ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA Now Available 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml EWING, N.J., March 29, 2016 Antares Pharma, Inc. (NASDAQ:
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationMerck Pipeline. October 15, 2009
Merck Pipeline October 15, 2009 2 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationIMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients
IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a Phase 2a trial A. B. Kimball 1, J. Krueger 2, T. Sullivan
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationcandidiasis and nasopharyngitis. No cases of suicidal ideation/behavior, major adverse cardiac events, or inflammatory bowel disease were reported.
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study 80 to 100% of BE ABLE 1 responders maintained a
More informationBayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International
More informationRequest for Special Authorization Enbrel
Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. Special Authorization requires that you request approval from Great-West Life for
More informationIxekizumab (plaque psoriasis)
IQWiG Reports Commission No. A17-07 Ixekizumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ixekizumab
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationEuropean Medicines Agency decision
EMA/730065/2010 European Medicines Agency decision P/1/2011 of 3 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira) (EMEA-000366-PIP01-08-M03)
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More information